Home / People / Frances Lowe

Frances Lowe

Associate
Patent Attorney

Portrait of Frances Denney

Frances Lowe

Associate
Patent Attorney

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English

Frances is a Chartered UK and European Patent Attorney in the IP department, specialising in the Life Sciences space. Her practice focusses on patent prosecution, opposition and appeal work before the European Patent Office. Frances also has experience assisting on patent litigations, corporate due diligence, and freedom-to-operate matters. 

Frances has particular experience in the areas of CRISPR, RNAi, biomarkers, antibody technology, drug formulations and medical devices. More recently, Frances has also been involved in cross-sector technologies in the High-Tech and Life Sciences space, including digital biomarkers and AI-led screening techniques.

Prior to joining CMS, Frances worked for a start-up biotech company, helping to develop their R&D pipelines.

more less

Education

  • 2020 – CPA (Chartered Patent Attorney)
  • 2019 – EPA (European Patent Attorney)
  • 2016 – Certificate in IP Law – Queen Mary University of London, London
  • 2014 – MSc Drug Discovery and Pharma Management – UCL, London
  • 2013 – BSc Biochemistry – UCL, London
more less

Expertise

Feed

14/09/2020
An EPO Case Law Round-Up: Ad­ded Mat­ter
The EPO is well-known for its strict ap­proach to as­sess­ing amend­ments un­der the ad­ded mat­ter pro­vi­sion of Art­icle 123 of the European Pat­ent Con­ven­tion. This of­ten cre­ates com­plex leg­al scen­ari­os which...
Law-Now Life Sciences & Healthcare
25/06/2020
Su­preme Court De­cision - Re­gen­er­on v Kymab [2020] UK­SC 27
Who knew a mouse could cause so much trouble? The Su­preme Court handed down its judg­ment in the case of Re­gen­er­on v Kymab this week, rul­ing that the as­ser­ted claims of Re­gen­er­on’s European pat­ent EP1360287...
Law-Now Life Sciences & Healthcare
19/05/2020
Not Pat­entable – The end of the line for plants and an­im­als pro­duced by...
The highest ju­di­cial au­thor­ity at the EPO is­sued their opin­ion late last week in the con­tro­ver­sial G3/19 (Pep­per) case. Con­trary to pre­vi­ous de­cisions in G2/12 and G2/13 (To­mato/Broc­coli), the En­larged...
Law-Now Patent Attorneys
31/01/2020
A Short Guide: Pri­or­ity En­ti­tle­ment at the EPO
Art­icle 87 EPC Pri­or­ity right (1) Any per­son who has duly filed, in or for (a) any State party to the Par­is Con­ven­tion for the Pro­tec­tion of In­dus­tri­al Prop­erty or (b) any Mem­ber of the World Trade...
Law-Now Intellectual Property
20/12/2019
‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...
Law-Now Life Sciences & Healthcare
17/12/2019
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally...
Law-Now Life Sciences & Healthcare
19/09/2019
AI & pa­tient com­pli­ance
This art­icle looks at tech­no­logy in the area of pa­tient com­pli­ance, an area where AI is hav­ing a huge im­pact on the life sci­ences in­dustry. Tech­no­lo­gies fa­cil­it­at­ing pa­tient com­pli­ance raise a host...
Publication
13/09/2019
SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...
Law-Now Life Sciences & Healthcare
30/05/2019
EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from med­ic­al...
The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc.'s European pat­ent ap­plic­a­tion (EP07837908.8), the claimed chem­ic­al...
Law-Now Life Sciences & Healthcare